Investor Relations

Hamilton Thorne (TSXV:HTL) designs, manufactures and distributes precision instruments, consumables, software and services for the fertility, stem cell and development biology research markets.

Its novel solutions reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets.

Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Specific applications include the reducing time in developing transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and higher yields for many cell procedures.

Hamilton Thorne’s CASA (Computer Assisted Sperm Analysis) image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. These systems assist researchers and clinicians in analyzing sperm motility and other characteristics in human fertility, toxicology and animal applications.

Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics.

With the XYClone, I have been able to take a process that took months and reduce it to days" Kathy Mohr, University of North Carolina, Transgenic Resource Center.

Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical.

Stock Quote

HAMILTON THORNE LTD: 0.89 (-0.03 - -3.26%)
6/23/2017, 3:41pm
S&P/TSX Venture Composite Index: 777.25 (+6.18 - +0.80%)
6/23/2017, 4:20pm

IR Contacts

David Wolf, CEO & President
Hamilton Thorne Ltd.
978-921-2050
ir [AT] hamiltonthorne [DOT] com

Michael Bruns, Chief Financial Officer
Hamilton Thorne Ltd.
978-921-2050
ir [AT] hamiltonthorne [DOT] com